Award
National Cancer Institute 5R37CA246239-07
Potentiating Checkpoint Blockade by Cross-Priming Tumor-Reactive T cells with In Situ Vaccination
Recipient
National Cancer Institute (NCI)
Award Amount
$351,924.00
Ceiling
$351,924.00
Awarded
January 29, 2026
Identifier
5R37CA246239-07
Research grant awarded by the National Cancer Institute to study in situ vaccine therapy combined with checkpoint blockade for cancer treatment.
Description
This is a research grant award from the National Cancer Institute for a project titled "Potentiating Checkpoint Blockade by Cross-Priming Tumor-Reactive T cells with In Situ Vaccination." The project aims to investigate mechanisms of in situ vaccine therapy and its combination with checkpoint blockade in cancer treatment.